Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

Volume: 371, Issue: 13, Pages: 1189 - 1197
Published: Sep 24, 2014
Abstract
Background Many patients with severe asthma require regular treatment with oral glucocorticoids despite the use of high-dose inhaled therapy. However, the regular use of systemic glucocorticoids can result in serious and often irreversible adverse effects. Mepolizumab, a humanized monoclonal antibody that binds to and inactivates interleukin-5, has been shown to reduce asthma exacerbations in patients with severe eosinophilic asthma. Methods In...
Paper Details
Title
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
Published Date
Sep 24, 2014
Volume
371
Issue
13
Pages
1189 - 1197
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.